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Abstract
Introduction. We aimed to investigate survivin and its splice variants DEx3 and 2B expressions in pituitary 
adenomas and normal pituitary glands using immunohistochemistry. 
Material and methods. The study group consisted of eight pituitary adenomas: five of non-functional tumors, 
two of GH-secreting tumors, and one PRL-secreting tumor. Eight healthy pituitary tissue samples obtained 
after autopsy served as controls. 
Results. Survivin expression was found in 87.5% of the study group and 100% of the controls. A positive staining 
of survivin 2B was found in 62.5% of pituitary adenomas and 100% of controls. Survivin DEx3 was recognized in 
25% of pituitary adenomas and 12.5% of normal pituitary glands. There was significantly lower immunoreactivity 
of survivin 2B in pituitary adenomas when compared with normal pituitary glands (p = 0.0498). 
Conclusions. Survivin and its splice variants might be involved to some extent in benign tumor growth of pituitary 
adenomas. However, survivin cannot be regarded as a candidate for targeted therapy or molecular biomarker 
of pituitary adenomas. (Folia Histochemica et Cytobiologica 2017, Vol. 55, No. 1, 21–25)
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Introduction
Sporadic pituitary adenomas are frequently visualized 
during radiological examination or autopsy indicat-
ing their significant prevalence in up to 17% of the 
population [1]. Clinically relevant pituitary adenomas 
are less frequent, though they are among the most 
common tumors of the central nervous system [2, 3]. 
The pathogenesis of pituitary tumorigenesis still 
remains unclear [4–6]. Pituitary adenomas arise from 
monoclonal growth and pituitary tumor transforming 
gene (PTTG) plays an important role in their devel-
opment [7, 8]. However, the pathogenesis of pituitary 
adenomas is complex and many other factors are 
suggested to be involved in their development and 
progression [9–12]. 
Survivin is a member of the IAP (inhibitor of ap-
optosis protein) family and plays an important role 
in cell division [13]. Survivin inhibits apoptosis by 
interaction with caspase-3 and -7. Another mechanism 
of apoptosis inhibition is related to the blocking of 
mitochondrial release of Smac/DIABLO complex 
and direct binding to IAP3 (inhibitor of apoptosis 
protein 3).
Survivin is involved in cancerogenesis and its 
enhanced expression has been found in many cancer 
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types [13–15]. It has been suggested to be associ-
ated with higher tumor stage and cancer aggres-
siveness. Post-transcriptional phosphorylation is 
responsible for alternative survivin transcripts ratios, 
which may influence the regulatory balance between 
cytoprotection and proapoptotic action. The full-
length transcript coexists with four splice isoforms: 
DEx3, 3B, 2B, and 2A which have different biology. 
In general, survivin DEx3 and 3B are considered 
anti-apoptotic, while 2B and 2A have pro-apoptotic 
properties. Moreover, survivin transcripts ratios might 
predict the response to chemotherapy [13].
Survivin can be expressed in healthy tissues with 
high proliferation potential, but the level of expres-
sion is much lower than in cancer cells. Survivin has 
been also detected in premalignant lesions, such as 
breast adenomas and colon polyps. Importantly, in 
precancerous tumors survivin was found mainly in 
the cytoplasm, while in cancers it dominated in the 
nuclear compartments [13]. 
Survivin has been investigated as a potential 
molecular biomarker of pituitary adenomas, but the 
obtained results are conflicting [16–20]. By using 
RT-qPCR method [21], in contrast to malignant en-
docrine tumors, we did not find over-expression of 
survivin and its splicing variants in pituitary adenomas, 
even if associated with local invasiveness. Therefore, 
the aim of this study was to evaluate survivin and its 
splicing variants survivin 2B and DEx3 expression in 
pituitary adenomas at the protein level by the use of 
semi-quantitative immunohistochemistry.
Material and methods
Pituitary tissues. The study group consisted of eight tissue 
samples of pituitary adenomas: five of non-functional tu-
mors, two of GH-secreting tumors, and one PRL-secreting 
tumor. Eight healthy pituitary tissue samples obtained from 
autopsy cases due to fatal trauma served as controls. Re-
moved pituitary tissues were fixed in 10% formalin and 
embedded in paraffin wax. The study was approved by the 
local ethics committee, and informed written consent was 
obtained from each patient. 
Immunohistochemical staining. Tissues were fixed in for-
malin, embedded in paraffin and 5-µm sections were taken. 
Reactions were carried out with the use of rabbit monoclonal 
anti-survivin antibody (dilution 1:250, Abcam, ab76424), 
rabbit polyclonal anti-survivin DEx3 antibody (dilution 
1:250, Abcam, ab3731), rabbit polyclonal anti-survivin 2B 
antibody (dilution 1:250, Abcam, ab3729). Reactions were 
visualized through subsequent incubations with a solution of 
biotinylated antibodies, streptavidin-horseradish peroxidase 
complex and diaminobenzidine (DAB) chromogen. 
The intensity of survivin/survivin 2B/survivin DEx3 ex-
pressions was evaluated using the modified semi-quanti-
tative immunoreactive score (IRS) approach, according 
to Remmele and Stegner [22], taking into account the 
percentage of positively stained cells (PP) (in the range 
of 0 to 4 points) and the staining intensity (SI) (in the 
range of 0 to 3 points). The total score ranges from 0 to 
12 points (IRS = SI×PP). Furthermore, the final score was 
presented on a five point scale (0 to 4 points) according 
to the formulas: 1–2 IRS points correspond to 1 point, 
3–4 IRS points — 2 points, 6–8 IRS points — 3 points, 
9–12 IRS points — 4 points.
Statistical analysis. Statistical analysis was performed with 
MedCalc version 15.8 (MedCalc Software bvba, Ostend, 
Belgium). P-value less than 0.05 indicated statistical signi-
ficance. A comparison of the analyzed parameters between 
two groups was performed by the Mann-Whitney U test.
Results
Characteristics of the study group and the immuno-
reactivity of survivin and its splice variants 2B and 
DEx3 expressions are provided in Table 1. 
Table 1. Characteristics and survivin/survivin 2B/survivin DEx3 expressions in the study group
Case  
No.
Hormonal activity  
of the tumor
Sex (F — female,  
M — male)
Age 
(years)
Size 
[mm]
IHC staining intensity
Survivin Survivin 2B Survivin DEx3
1. Non-functioning M 68 40 0 0 0
2. GH-secreting F 56 17 1 0 0
3 Non-functioning M 47 45 1 1 0
4. Non-functioning F 42 31 2 1 0
5 Non-functioning F 42 37 1 1 0
6. PRL-secreting M 57 20 4 0 2
7. GH-secreting F 45 21 4 3 2
8. Non-functioning F 48 33 2 3 0
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The median age of patients with pituitary ade-
nomas was 47.5 years (interquartile range (IQR) 
43.5–56.5 yrs) and that of control subjects 48.0 years 
(IQR 44–56.5 yrs) (p = 0.9547). Survivin expression 
was found in 87.5% of the study group and in 100% 
of the controls. A positive staining of survivin 2B was 
found in 62.5% of pituitary adenomas and in 100% 
of controls. Survivin DEx3 was recognized in 25% of 
pituitary adenomas and in 12.5% of normal pituitary 
glands (Table 1). Immunostaining of pituitary adeno-
mas was not uniform. Survivin and its splice variants 
DEx3 and 2B were predominantly localized in the 
cytoplasm of pituitary tumors and controls (Fig. 1). 
Figure 2 shows staining of survivin 2B in a pituitary 
adenoma and normal pituitary gland. The immunore-
activity of survivin 2B (p = 0.0498) was significantly 
lower in pituitary adenomas when compared with 
normal pituitary glands (Fig. 3). 
Discussion
We aimed to investigate survivin and its splice variants 
DEx3 and 2B expression in pituitary adenomas and 
normal pituitary glands using immunohistochemistry. 
We found down-regulation of survivin 2B expression 
in pituitary adenomas, while the intensity of survivin 
and survivin DEx3 immunoreactivity did not differ 
between pituitary tumors and normal glands. To the 
best of our knowledge, this is the first study evaluating 
immunohistochemical expression of survivin and its 
splice variants DEx3 and 2B in pituitary adenomas. 
Survivin expression in pituitary tumors has been 
studied previously, but results are contradictory. We 
Figure 1. Cytoplasmatic localization of the expression of survivin (A), survivin DEx3 (B) and survivin 2B (C) in pituitary tumor. 
The studied proteins were visualized by immunohistochemistry as described in Material and methods. Scale bars: 100 µm.
A B C
Figure 2. Comparative immunohistochemical staining for survivin 2B in non-functioning pituitary adenoma (A) and normal 
pituitary gland (B). Scale bars: 100 µm.
A B
Figure 3. Comparison of survivin 2B expression in pituitary 
adenomas and normal pituitary glands. Central box repre-
sents the values from the lower to upper quartile (25th to 75th 
percentile). The middle line represents the median. Whiskers 
extend to a multiple of 1.5× the distance of the upper and 
lower quartile, respectively. 
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have previously found that the expression of survivin 
and its splice variants DEx3 and 2B at the mRNA 
level in 50 pituitary adenomas was similar to that in 
12 normal pituitary glands [21]. Formosa et al. ana-
lyzed immunohistochemical expression of survivin in 
pituitary adenomas and healthy pituitary tissues [19]. 
They did not find the expression of survivin in normal 
pituitary glands, whereas its expression in pituitary 
tumors was extremely low. Zhang et al. observed 
higher survivin expression in invasive pituitary ade-
nomas, whereas other authors did not confirm these 
findings [17, 20, 21].
Increased cell proliferation and decreased apopto-
sis [5] were found in pituitary adenomas, so the latter 
might explain observed decreased survivin 2B expres-
sion. The regulation of cell proliferation in invasive 
pituitary adenomas is thought to be disturbed [5], 
although it has not been reflected in our study by 
potential up-regulation of anti-apoptotic proteins 
survivin and survivin DEx3. Survivin 2B down-regu-
lation has been also observed in gastric cancers, with 
further decrease in late-stage tumors [23]. Moreover, 
decreased survivin 2B expression had prognostic value 
in gastric cancers, which supports its potential role 
in tumor progression. In view of these observations, 
the down-regulation of survivin 2B in pituitary ade-
nomas might also suggest its potential involvement in 
pituitary neoplastic transformation. Despite pituitary 
adenomas being benign lesions with slow progression, 
some of them are invasive and recurrent. Therefore, 
our results might have clinical implications indicat-
ing potential therapeutic targets. Interestingly, we 
have not found over-expression of survivin DEx3, 
which is considered a negative prognostic marker in 
many malignant tumors [13]. However, we observed 
cytoplasmic staining of survivin and its splice vari-
ants, which is consistent with other studies of benign 
lesions, in contrast to nuclear staining observed in 
malignant cells [13].
In summary, our preliminary data suggest that 
survivin and its splice variants might be involved 
to some extent in benign tumor growth of pituitary 
adenomas. However, survivin cannot be regarded as 
a candidate for targeted therapy or molecular bio-
marker of pituitary adenomas. 
Limitation of the study
Due to the limited sample size we were not able to 
investigate a possible association between survivin/its 
splice variants DEx3 and 2B and hormonal activity of 
the pituitary adenomas. 
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